Amoxapine is a second-generation tricyclic dibenzoxazepine antidepressant, chemically distinct from the dibenzodiazepines, dibenzocycloheptenes, and dibenzoxepines. It has a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephirine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. Amoxapine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

Amoxapine SSRI Pathway References